Compare Ascendis Pharma A/S (ASND) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Novartis AG — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 17.7× Ascendis Pharma A/S's market cap, and Novartis AG pays a 3.07% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NVS | |
|---|---|---|
Market Cap | $16.67B | $295.37B |
Sector | Health | Health |
52-Week High | $277.18 | $168.62 |
52-Week Low | $189.74 | $119.31 |
Enterprise Value | $17.04B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
